These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 15111692)
21. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Ziemssen T; Neuhaus O; Hohlfeld R Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654 [TBL] [Abstract][Full Text] [Related]
22. Accurate quantification methods to evaluate cervical cord atrophy in multiple sclerosis patients. Carbonell-Caballero J; Manjón JV; Martí-Bonmatí L; Olalla JR; Casanova B; de la Iglesia-Vayá M; Coret F; Robles M MAGMA; 2006 Nov; 19(5):237-46. PubMed ID: 17115124 [TBL] [Abstract][Full Text] [Related]
23. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Gordon-Lipkin E; Chodkowski B; Reich DS; Smith SA; Pulicken M; Balcer LJ; Frohman EM; Cutter G; Calabresi PA Neurology; 2007 Oct; 69(16):1603-9. PubMed ID: 17938370 [TBL] [Abstract][Full Text] [Related]
24. Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA. Neacsu V; Jasperse B; Korteweg T; Knol DL; Valsasina P; Filippi M; Barkhof F; Rovaris M; Vrenken H; J Magn Reson Imaging; 2008 Sep; 28(3):559-65. PubMed ID: 18777529 [TBL] [Abstract][Full Text] [Related]
25. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M; Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268 [TBL] [Abstract][Full Text] [Related]
26. Seeing injectable ms therapies differently: they are more similar than different. Johnson KP; Fox RJ; Arnold DL Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129 [No Abstract] [Full Text] [Related]
27. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Chen JT; Collins DL; Atkins HL; Freedman MS; Galal A; Arnold DL; Neurology; 2006 Jun; 66(12):1935-7. PubMed ID: 16801665 [TBL] [Abstract][Full Text] [Related]
28. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Tedeschi G; Lavorgna L; Russo P; Prinster A; Dinacci D; Savettieri G; Quattrone A; Livrea P; Messina C; Reggio A; Bresciamorra V; Orefice G; Paciello M; Brunetti A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Patti F; Salemi G; Cammarata E; Simone IL; Salvatore M; Bonavita V; Alfano B Neurology; 2005 Jul; 65(2):280-5. PubMed ID: 16043800 [TBL] [Abstract][Full Text] [Related]
29. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Comi G; Martinelli V; Rodegher M; Moiola L; Leocani L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Preziosa P; Ravnborg M; Rieckmann P; Rocca MA; Wynn D; Young C; Filippi M Mult Scler; 2013 Jul; 19(8):1074-83. PubMed ID: 23234810 [TBL] [Abstract][Full Text] [Related]
30. Therapy with glatiramer acetate for multiple sclerosis. Munari L; Lovati R; Boiko A Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077 [TBL] [Abstract][Full Text] [Related]
31. Disease modifying treatment in multiple sclerosis. Fuller GN; Bone I J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780 [No Abstract] [Full Text] [Related]
35. Extended use of glatiramer acetate (Copaxone) for MS. Greenstein JI Neurology; 1999 Mar; 52(4):897-8. PubMed ID: 10078765 [No Abstract] [Full Text] [Related]
36. Evidence for use of glatiramer acetate in multiple sclerosis. Comi G; Hartung HP; Martinelli Boneschi F Lancet Neurol; 2005 Feb; 4(2):75-6; discussion 76-7. PubMed ID: 15664539 [No Abstract] [Full Text] [Related]
37. Evidence for use of glatiramer acetate in multiple sclerosis. Caramanos Z; Arnold DL Lancet Neurol; 2005 Feb; 4(2):74-5; discussion 76-7. PubMed ID: 15664538 [No Abstract] [Full Text] [Related]
38. Psychiatric manifestations in multiple sclerosis patients and multiple sclerosis in psychiatric patient. Fragoso YD; Brooks JB Arq Neuropsiquiatr; 2009 Dec; 67(4):1167-8. PubMed ID: 20069241 [No Abstract] [Full Text] [Related]
39. Interventions for the prevention of brain atrophy in multiple sclerosis : current status. Rovaris M; Filippi M CNS Drugs; 2003; 17(8):563-75. PubMed ID: 12775193 [TBL] [Abstract][Full Text] [Related]
40. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. De Stefano N; Giorgio A; Battaglini M; Rovaris M; Sormani MP; Barkhof F; Korteweg T; Enzinger C; Fazekas F; Calabrese M; Dinacci D; Tedeschi G; Gass A; Montalban X; Rovira A; Thompson A; Comi G; Miller DH; Filippi M Neurology; 2010 Jun; 74(23):1868-76. PubMed ID: 20530323 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]